Department of Medicine
Daniel Catenacci specializes in gastrointestinal malignancies, including esophageal, gastric, pancreatic, hepatobiliary, colorectal, appendiceal, neuroendocrine, and anal cancers, as well as gastrointestinal stromal tumors. He currently focuses on the basic laboratory investigation of normal and cancer cell signaling and evaluation of novel molecular inhibitory targets based on these signaling pathways with particular attention to receptor tyrosine kinases. His ultimate goal is developing novel inhibitory agents to treat gastroesophageal and aerodigestive malignancies.
He is principal investigator for various gastrointestinal clinical trials, including a pancreatic cancer trial evaluating a novel hedgehog pathway inhibitor combined with gemcitabine chemotherapy. He leads the translational laboratory research effort for these clinical trials for the Gastrointestinal Oncology program.
Catenacci has authored and presented papers and lectures on gastrointestinal malignancies. He has performed Phase I, II, and III clinical trials, drug development, and the validation of molecular markers to predict patient outcomes.
He was an intern and a resident at UCLA Medical Center and is a fellow at the University of Chicago Medical Center. Catenacci received his MD from Wayne State University School of Medicine (2003) and his BS from the University of Waterloo, Canada (1999).
Catenacci joined the University of Chicago faculty in 2010.